Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AAD-NPF releases first guidelines for nonbiologic treatments of psoriasis

Publish date:: March 11, 2020

Key clinical point: Nonbiologic systemic therapies still have a place for treatment of psoriasis.

Major finding: Oral apremilast is recommended for moderate to severe psoriasis

Study details: Guidelines developed by a committee of the American Academy of Dermatology and National Psoriasis Foundation.

Disclosures: Dr. Menter and Dr. Elmets disclosed financial relationships with numerous pharmaceutical companies. Other authors/work group members also had disclosures related to pharmaceutical manufacturers, and several had no disclosures.

Citation:

Menter A et al. J Am Acad Derm. 2020 Feb 28. doi: 10.1016/j.jaad.2020.02.044.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Psoriasis

Synovial, skin gene expression differences may explain PsA treatment responses,

Tildrakizumab for psoriasis shows durable efficacy over 5 years,

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials,

Study highlights differences between White and Latino patients with psoriasis,

Shingrix effective in older adults with preexisting immune-mediated disorders,